Service 01
Literature review & evidence synthesis
We turn a scattered clinical evidence base into a structured,
defensible package that answers the questions HTA bodies actually ask —
built to submission standard from the outset, not retrofitted afterwards.
Systematic literature review
- Systematic reviews to submission standard
- Targeted literature reviews
- Rapid reviews for early decisions
- Protocol development and PRISMA reporting
Evidence synthesis
- Indirect treatment comparison
- Network meta-analysis
- Matching-adjusted indirect comparison
- Multi-level network meta-regression
Localisation
- Adaptation of global reports to local dossiers
- Alignment to regional methods guidance
- Country-specific evidence gap assessment
Service 02
Health economic modelling
Economic models that translate a clinical benefit into a value
argument a payer will accept — transparent in their assumptions, robust
under scrutiny, and structured so a reviewer can follow every calculation.
Cost-effectiveness models
- Early-stage and concept models
- Global core models for local adaptation
- Disease-agnostic model frameworks
- Independent model QC and validation
Health economic tools
- Budget impact models
- Cost-consequence models
- Cost-per-response models
- Price–volume trade-off analysis
- Bespoke tools built to brief
Localisation
- Adaptation of global models to local cost bases
- Country-specific input sourcing
- Submission-ready model documentation
Therapeutic areas:
oncology, immunology, neurosciences, respiratory, vaccines and eyecare.
Service 03
Statistical data analysis
Rigorous analysis, framed around the decision it has to support.
We work from the trial data upward to produce the estimates a model needs and
the evidence a regulator or payer will interrogate.
Health economics & outcomes
- Quality of life analysis
- Health-state utility value derivation
- Survival analysis and extrapolation
- Treatment switching adjustment
- Adverse event and disutility analysis
- Cost input derivation
Post-hoc analysis of clinical trials
- Subgroup and sensitivity analysis
- Re-analysis to address HTA critique
- Analyses supporting peer-reviewed publication
- Statistical analysis plan development
Service 04
Health technology assessment
Submission strategy and delivery across markets, from early
pipeline evaluation through launch and beyond — anticipating where an
assessment will be challenged, and building the evidence to meet it.
HTA & submission strategy
- Reimbursement submission strategy
- Predicted HTA outcome analysis
- Risk identification and mitigation
- Competitive benchmarking
Trial design & evidence planning
- Development programme assessment
- Evidence gap analysis against HTA needs
- Endpoint and comparator selection support
Early evaluation & decision-making
- Early pipeline asset evaluation
- Trade-off assessment
- Business development opportunity appraisal
